These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 17123392

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inhibitors in congenital coagulation disorders.
    Key NS.
    Br J Haematol; 2004 Nov; 127(4):379-91. PubMed ID: 15521914
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Recent improvements in the clinical treatment of coagulation factor inhibitors.
    Franchini M, Lippi G.
    Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).
    Chitlur M, Warrier I, Rajpurkar M, Lusher JM.
    Haemophilia; 2009 Sep; 15(5):1027-31. PubMed ID: 19515028
    [Abstract] [Full Text] [Related]

  • 12. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
    Astermark J, Morado M, Rocino A, van den Berg HM, von Depka M, Gringeri A, Mantovani L, Garrido RP, Schiavoni M, Villar A, Windyga J, EHTSB.
    Haemophilia; 2006 Jul; 12(4):363-71. PubMed ID: 16834735
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
    Astermark J.
    Haemophilia; 2006 Jul; 12 Suppl 3():52-60. PubMed ID: 16683997
    [Abstract] [Full Text] [Related]

  • 17. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
    Astermark J.
    Haemophilia; 2006 Dec; 12 Suppl 6():8-13; discussion 13-4. PubMed ID: 17123388
    [Abstract] [Full Text] [Related]

  • 18. Immunological aspects of inhibitor development.
    Reding MT.
    Haemophilia; 2006 Dec; 12 Suppl 6():30-5; discussion 35-6. PubMed ID: 17123391
    [Abstract] [Full Text] [Related]

  • 19. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U.
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.